Hansa Biopharma Announces Positive Topline Data From Imlifidase Phase 2 Study

Hansa Biopharma AB HNSA:

• HANSA BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM THE IMLIFIDASE PHASE 2 STUDY IN ANTIBODY MEDIATED REJECTION (AMR) EPISODES POST KIDNEY TRANSPLANTATION

• HANSA PLANS TO PUBLISH FULL DATASET FROM STUDY IN 2023

• TOPLINE DATA ASSOCIATED WITH PRIMARY ENDPOINT SHOWS THAT IMLIFIDASE HAS SIGNIFICANTLY SUPERIOR EFFICACY

• HANSA BIOPHARMA - EFFICACY DATA OF DRUG IS SUPERIOR WHEN COMPARED TO PLASMA EXCHANGE IN REDUCING DSAS DURING 5 DAYS FOLLOWING START OF TREATMENT